Stentys is listed on the NYSE Euronext [STNT] and offers simple, innovative solutions to interventional cardiologists when treating the challenging disease of their patients. When faced with a situation where choosing the appropriate stent size is not easy, such as in acute myocardial infarction or in bifurcation lesions, the STENTYS platform provides an efficient and elegant new treatment approach. The STENTYS stent can cater for a range of vessel diameters and is able to adapt itself acutely to different diameters along the vessel.  It can also continue to expand over time to remain apposed to the vessel, even when there is positive remodelling. Stentys was founded by Gonzague Issenmann and Professor Jacques Seguin. Sofinnova Partners was the first investor in the company.

Medical Devices

Antoine Papiernik

Antoine Papiernik is a Managing Partner at Sofinnova Partners, which he joined in 1997. Antoine has been an initial investor and active board member in public companies like Actelion, ProQR, Shockwave Medical,  NovusPharma (then sold to CTI), Movetis (then sold to Shire), Mainstay, Pixium Vision and...